Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
03 06 2021
Historique:
pubmed: 25 11 2020
medline: 14 5 2021
entrez: 24 11 2020
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented global toll and vaccination is needed to restore healthy living. Timely inclusion of children in vaccination trials is critical. We surveyed caregivers of children seeking care in 17 Emergency Departments (ED) across 6 countries during the peak of the pandemic to identify factors associated with intent to participate in COVID-19 vaccine trials. Questions about child and parent characteristics, COVID-19 expressed concerns and parental attitudes toward participation in a trial were asked.Of 2768 completed surveys, 18.4% parents stated they would enroll their child in a clinical trial for a COVID-19 vaccine and 14.4% would agree to a randomized placebo-controlled study. Factors associated with willingness to participate were parents agreeing to enroll in a COVID-19 vaccine trial themselves (Odds Ratio (OR) 32.9, 95% Confidence Interval (CI) (21.9-51.2)) having an older child (OR 1.0 (1.0-1.01)), having children who received all vaccinations based on their country schedule (OR 2.67 (1.35-5.71)) and parents with high school education or lower (OR 1.79 (1.18-2.74)). Mothers were less likely to enroll their child in a trial (OR 0.68 (0.47-0.97)). Only one fifth of families surveyed will consider enrolling their child in a vaccine trial. Parental interest in participation, history of vaccinating their child, and the child being older all are associated with parents allowing their child to participate in a COVID vaccine trial. This information may help decision-makers and researchers shape their strategies for trial design and participation engagement in upcoming COVID19 vaccination trials.

Identifiants

pubmed: 33228458
doi: 10.1080/21645515.2020.1834325
pmc: PMC8115755
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1607-1611

Références

Cancer Nurs. 2010 Jan-Feb;33(1):11-8
pubmed: 19926980
Arch Dis Child. 2006 Feb;91(2):112-6
pubmed: 16246853
Res Nurs Health. 2006 Jun;29(3):223-32
pubmed: 16676342
JAMA Pediatr. 2013 Jun;167(6):561-6
pubmed: 23546617
Qual Health Res. 2007 Mar;17(3):311-22
pubmed: 17301340
Anesthesiology. 2003 Mar;98(3):603-8
pubmed: 12606901
J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):309-13
pubmed: 20479689
Paediatr Nurs. 2007 Oct;19(8):14-8
pubmed: 17970358
PLoS One. 2014 Jul 24;9(7):e102505
pubmed: 25057914
BMC Pediatr. 2007 Mar 09;7:12
pubmed: 17349034
J Clin Oncol. 2002 Apr 15;20(8):2109-17
pubmed: 11956272
J Perinatol. 2002 Jan;22(1):57-63
pubmed: 11840244
J Pediatr. 2003 May;142(5):554-9
pubmed: 12756389
Cancer Pract. 1999 Sep-Oct;7(5):248-56
pubmed: 10687594
PLoS Med. 2010 Nov 09;7(11):e1000368
pubmed: 21085696
Vaccine. 2014 Aug 20;32(37):4708-12
pubmed: 24768580
J Med Ethics. 2011 Sep;37(9):544-51
pubmed: 21478415
J Med Ethics. 1992 Jun;18(2):86-93
pubmed: 1619628
J Pediatr. 2007 Nov;151(5):532-7, 537.e1-5
pubmed: 17961701
Trials. 2016 Jan 09;17:17
pubmed: 26745891

Auteurs

Ran D Goldman (RD)

The Pediatric Research in Emergency Therapeutics (Pretx) Program, Division of Emergency Medicine, Department of Pediatrics, University of British Columbia, and BC Children's Hospital Research Institute, Vancouver, BC, Canada.

Georg Staubli (G)

Emergency Department, University Children's Hospital Zurich, Zurich, Switzerland.

Cristina Parra Cotanda (CP)

Pediatric Emergency Department, Hospital Sant Joan De Déu Barcelona, Barcelona, Spain.

Julie C Brown (JC)

Department of Pediatrics, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA, USA.

Julia Hoeffe (J)

Pediatric Emergency Medicine, Inselspital University Hospital of Bern, Bern, Switzerland.

Michelle Seiler (M)

Emergency Department, University Children's Hospital Zurich, Zurich, Switzerland.

Renana Gelernter (R)

Pediatric Emergency Medicine Unit, Shamir Medical Center (Assaf Harofeh), and Sackler Faculty of Medicine, Tel Aviv University, Be'er Ya'akov, Israel.

Jeanine E Hall (JE)

Division of Emergency and Transport Medicine, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, CA, USA.

Mark A Griffiths (MA)

Division of Pediatric Emergency Medicine, Children's Healthcare of Atlanta, Emory School of Medicine, Atlanta, GA, USA.

Adrienne L Davis (AL)

Pediatric Emergency Medicine, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.

Sergio Manzano (S)

Department of Pediatric Emergency Medicine, Geneva Children's Hospital, Geneva University Hospitals, and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Ahmed Mater (A)

Pediatric Emergency Medicine, Jim Pattison Children's Hospital, and University of Saskatchewan, Saskatoon, SK, Canada.

Sara Ahmed (S)

Department of Emergency Medicine, Mary Bridge Children's Hospital, Tacoma, WA, USA.

David Sheridan (D)

Emergency Medicine, Oregon Health & Science University, Doernbecher Children's Hospital, Portland, OR, USA.

Matt Hansen (M)

Emergency Medicine, Oregon Health & Science University, Doernbecher Children's Hospital, Portland, OR, USA.

Samina Ali (S)

Departments of Pediatrics and Emergency Medicine, Stollery Children's Hospital, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.

Graham C Thompson (GC)

Pediatrics and Emergency Medicine, Alberta Children's Hospital and University of Calgary, Calgary, AB, Canada.

Naoki Shimizu (N)

Division of Critical Care, Department of Pediatrics, St. Marianna University School of Medicine, Tokyo, Japan.

Eileen J Klein (EJ)

Department of Pediatrics, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH